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The use of psychotropic drugs in France has increased over the
last 2 decades and is considered the highest in Europe [1–3]. The
main drugs are anxiolytics, antidepressants, hypnosedative and
neuroleptic agents. All are responsible for severe adverse drug
reactions and addiction associated with chronic or excessive
consumption over several months. Besides inter-individual
variability related to genetic or pathophysiological factors, the
types and occurrence of adverse events vary across the psychotro-
pic drug classes. Drug-related adverse events commonly observed
are movement disorders and spasticity (with neuroleptic agents);
cardiovascular and anticholinergic effects (antidepressant drugs);
and confusion and changes in cognitive status (sedative and
anxiolytics agents). However, unlikely adverse events could also
occur. To prevent drug abuse or misuse, psychotropic drug
prescriptions are now closely controlled and monitored in terms
of dosage, therapeutic indication and duration with national public
policies [1,3]. However, the use of psychotropic agents (sometimes
in the long-term) can be necessary in rehabilitation units to treat
neurological, psychological or behavioural disorders such as
epilepsy, depression, anxiety, agitation or sleep disorders.
In brain injury rehabilitation units (BIRU), particular attention
must be paid to psychotropic drugs for their negative effect on
central nervous system recovery and cognition after stroke or brain
injury [4]. Moreover, the effects of psychotropic drugs are usually
studied in the general population but not speciﬁcally in patients
with brain injury. Thus, little is known about the adverse and
cumulative effects of psychotropic drugs in such patients.
This present study aimed to examine the prevalence of
psychotropic drug use in an inpatient BIRU rehabilitation
population. We conducted a one-day quick-audit of psychotropic
drug prescription in the BIRU of our hospital on July 3, 2014 to
assess the prescription prevalence and type of prescriptions and to
evaluate professional practice. Hospitalized patients receiving
antiepileptics, antidepressants, benzodiazepines (BZDs), neuro-
leptics and histamine-H1 antagonists were included and their
treatments studied. Data on patients and treatments were
collected from patient medical ﬁles and computerized medical
prescriptions (computerized physician order software Phedra1).
In total, 55 patients (mean age 51.9  18.3 years; 38 males) were
hospitalized on the day of the audit. Most (n = 33; 60%) were admitted
for vascular aetiology (stroke or cerebral haemorrhage), 10 (18%)
severe traumatic brain injury (TBI) and 8 (15%) other types of brain
injury (autoimmune or infectious encephalitis). A total of 46 (84%)
were receiving at least one psychotropic drug and 31 (56%) had
received a prescription before hospitalization. The prevalence of thishttp://dx.doi.org/10.1016/j.rehab.2015.10.004
1877-0657/ 2015 Elsevier Masson SAS. All rights reserved.type of prescription was 1.8-fold higher than in the French general
population [3].
The characteristics of drug prescriptions are in the Table 1. For
the 38% of psychotropic drugs that were introduced during
hospitalization, the prescription was explicitly justiﬁed in the
patient’s medical record in only two thirds of cases (62%).
Therefore, the implementation of clinical guidelines could be
helpful for physicians in choosing and justifying the most
appropriate drugs, especially after stroke, as was recently
published for TBI [5]. Levetiracetam and pregabaline were the
2 second-generation antiepileptic drugs most-often prescribed.
Norepinephrin and/or serotonin re-uptake inhibitors (NSRI and/or
SSRI) were the most common antidepressants used: paroxetine
and ﬂuoxetine (SSRIs) and venlafaxine (NSRI).
Neurobehavioural sequelae are commonly described in reha-
bilitation medicine after stroke or TBI [6,7]. The incidence of
seizure has been extensively studied and ranges from 4% to 50%,
depending on the population studied [8–10]. Although data are
controversial, the risk of seizure would be 20- to 40-fold higher
after stroke than in the general population [8]. In our study, when
anti-convulsant medication was required, the use of a second-
generation antiepileptic drug such as levetiracetam was predomi-
nant. Pregabalin was exclusively used for neurological pain.
Indeed, these second-generation drugs have been recommended
over older-generation drugs (e.g., phenytoin or phenobarbital) for
both safety and efﬁcacy [10,11]. Moreover, most of these new-
generation drugs do not have clinically important enzyme-
inducing or -inhibiting effects involved in the management of
drug–drug interactions frequently observed in polymedicated
patients. Similarly, mood disorders such as depression and anxiety
are also frequent after stroke or TBI, with an estimated prevalence
of 30% [12]. The frequency of antidepressant drug prescriptions we
found (28%) supports these epidemiological data.
The BZD prescription analysis showed that alprazolam was
most represented in this study, which agrees with the French BZD
consumption survey [1]. However, the duration of BZD dose was
therefore higher (mean of 62 days/prescription) than usually
recommended by French guidelines (as short as possible)
[1]. Overall, 10% of our patients received co-prescription with
other BZDs or BZD-like agents (zopiclone or zolpidem), especially
for sleep disorders and agitation. Many patients receive a
prescription for anxiolytic or hypnosedative drugs during hospi-
talization: up to 33% to 60% of hospitalized patients [13]. The use of
these drugs is also not an exception in the BIRU. However, this type
of prescription should be performed cautiously and gradually
because of a risk of dependence after long-term treatment and
attention deﬁciency and deleterious effects on neuronal plasticity.
Therefore, anxioloytics and hypnosedative drugs should not be co-
prescribed and should be stopped as soon as possible when their
prescription is no longer needed, as for other psychotropic drugs.
Indeed, GABA agonists such as BZD could be responsible for a great
Table 1
Characteristics of prescriptions for 46 in-patients receiving psychotropic drugs.
Characteristics
Number of drugs prescribed/patient, mean  SD 10.1  4.2
Number of psychotropic drugs prescribed/patient, mean  SD 2.3  1.0
Number of patients receiving  2 psychotropic drugs 34 (74)
Duration of psychotropic drug treatment (days),
median (min–max)
48.5 [1–332]
Number of psychotropic drugs introduced during
hospitalization
17 (38)
Class of psychotropic drugs prescribed
Antiepileptic drugs 16 (35)
Antidepressant drugs 13 (28)
Benzodiazepines or benzodiazepine-like agents 11 (24)
Histamine-H1 antagonists 4 (9)
Neuroleptic drugs 2 (4)
Data are no. (%) unless indicated.
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distribution of receptors found in a number of areas, including
the spinal cord, cerebellum, limbic areas and cerebral cortex
[14]. Moreover, despite increasing evidence that psychotropic
agents may affect structural and/or functional plasticity, the beneﬁt
or deleterious effects of these drugs on neuroplasticity is currently
debated. Cellular and molecular imaging studies have revealed that
antiepileptics and antidepressants (SSRIs and tricyclic antidepres-
sants) could enhance the plasticity of neuronal connections by
amplifying intracellular signaling cascades [15]. Within the group of
neuroleptic agents, neuroplasticity would depend on the molecule:
ﬁrst-generation molecules (e.g., haloperidol) would be associated
with neurotoxic effects (decline in brain-derivated neurotrophic
factors), whereas second-generation agents such as olanzapine and
clozapine could promote neuroplasticity [15].
Our ﬁndings suggest a lack of evidence for the deleterious
effects of some psychotropic drugs in the recovery of brain-
damaged patients, especially after stroke, whereas current
recommendations restricting psychotropic prescription are based
on general population data. Speciﬁc studies including patients
with brain injury as well as speciﬁc recommendations are needed
for good clinical practice.
Finally, we found that behavioural disorders were rarely
managed with neuroleptics as compared with BZDs, which are
still the most commonly prescribed psychotropic agents despite a
beneﬁt-to-risk ratio that has yet to be demonstrated. This
observation could be explained by the prescribing habits of
physicians, which are mostly oriented to symptoms rather than
evidence-based medicine. Moreover, these compounds are known
to be deleterious for rehabilitation and could increase the risk of
stroke [16]. For these previous reasons, the use of BZDs and/or
neuroleptics should be reserved for very short-term second-line
therapy to treat behavioural disorders after TBI [5].
Despite the limitations of this one-day quick-audit (observa-
tional data, short time to collect data, limited number of patients),
this study allowed us to take a snap-shot of the prescription
characteristics in these cases and especially conﬁrms that
psychotropic drugs are widely used for the management of
rehabilitation in these cases. However, their use should be subject
to a beneﬁt/risk evaluation and must be amply justiﬁed to avoid a
deleterious effect on rehabilitation and functional recovery [17].
As described by Petrissans et al. in a 6-month psychotropic drug
prescription retrospective study [18], our ﬁndings demonstrate
that psychotropic treatments could be optimized in clinical
practice. According to the French Physical and Rehabilitation
Medicine Society (SOFMER) guidelines for evaluation, treatment
and follow-up concerning behavioural disorders, some speciﬁcpoints could be improved, such as the use of beta-blockers
(propranolol) for aggressiveness instead of BZDs in TBI patients
[5]. Moreover, the use of neuroleptics should be limited to loxapine
only for crisis emergency. Efforts will also be made to avoid BZD co-
prescription and to improve traceability and pharmacological
justiﬁcations in the patient’s medical ﬁle. In addition, systematic
and constant relevance assessment of pharmacological and/or
non-pharmacological treatment is essential to improve care.
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